[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kura Oncology (KURA)

Kura Oncology (KURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 836,148
  • Shares Outstanding, K 88,763
  • Annual Sales, $ 67,480 K
  • Annual Income, $ -278,670 K
  • EBIT $ -304 M
  • EBITDA $ -311 M
  • 60-Month Beta 0.32
  • Price/Sales 12.26
  • Price/Cash Flow N/A
  • Price/Book 4.66

Options Overview Details

View History
  • Implied Volatility 115.96% (-30.50%)
  • Historical Volatility 43.86%
  • IV Percentile 35%
  • IV Rank 15.56%
  • IV High 434.09% on 02/04/26
  • IV Low 57.32% on 08/18/25
  • Expected Move (DTE 4) 0.30 (3.01%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 95
  • Volume Avg (30-Day) 397
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 7,342
  • Open Int (30-Day) 7,986
  • Expected Range 9.58 to 10.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.88
  • Number of Estimates 6
  • High Estimate $-0.75
  • Low Estimate $-1.00
  • Prior Year $-0.66
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.53 +15.59%
on 04/29/26
10.03 -1.74%
on 04/21/26
+1.19 (+13.73%)
since 04/10/26
3-Month
7.53 +30.86%
on 03/30/26
10.03 -1.74%
on 04/21/26
+2.02 (+25.77%)
since 02/11/26
52-Week
5.45 +80.92%
on 08/11/25
12.49 -21.06%
on 11/14/25
+4.10 (+71.18%)
since 05/09/25

Most Recent Stories

More News
Kura Oncology's Commercial Launch Trajectory Will Either Validate or Undermine Its Valuation

Barchart Research What to Expect from KURA Earnings KURA Generated May 6, 2026 Current Price $9.56 EPS Estimate $$-0.88 Consensus Rating Strong Buy Average Move 1.98% Kura Oncology's Commercial Launch...

KURA : 9.82 (+4.25%)
Kura Oncology to Participate in Bank of America Securities Healthcare Conference

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 9.82 (+4.25%)
Kura Oncology to Report First Quarter 2026 Financial Results

SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 9.82 (+4.25%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 9.82 (+4.25%)
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated...

KURA : 9.82 (+4.25%)
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30...

KURA : 9.82 (+4.25%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 9.82 (+4.25%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 9.82 (+4.25%)
Kura Oncology: Q4 Earnings Snapshot

Kura Oncology: Q4 Earnings Snapshot

KURA : 9.82 (+4.25%)
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of...

KURA : 9.82 (+4.25%)

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Key Turning Points

3rd Resistance Point 9.69
2nd Resistance Point 9.60
1st Resistance Point 9.51
Last Price 9.82
1st Support Level 9.33
2nd Support Level 9.24
3rd Support Level 9.15

See More

52-Week High 12.49
Last Price 9.82
Fibonacci 61.8% 9.80
Fibonacci 50% 8.97
Fibonacci 38.2% 8.14
52-Week Low 5.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.